Quantitative analysis of factor P (Properdin) in monkey serum using immunoaffinity capturing in combination with LC–MS/MS

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Smith CA, Pangburn MK, Vogel CW, Müller-Eberhard HJ. Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J. Biol. Chem. 259(7), 4582–4588 (1984).
  Medline CASGoogle Scholar
• 2 Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281(4), 2128–2132 (2006).
  Medline CASGoogle Scholar
• 3 Sun Z, Reid KBM, Perkins SJ. The Dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling. J. Mol. Biol. 343(5), 1327–1343 (2004).
  Medline CASGoogle Scholar
• 4 Schwaeble WJ, Reid KBM. Does properdin crosslink the cellular and the humoral immune response? Immunol. Today 20(1), 17–21 (1999).
  Medline CASGoogle Scholar
• 5 Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat. Biotech. 25(11), 1265–1275 (2007).
  Medline CASGoogle Scholar
• 6 Roskos LK, Schneider A, Vainshtein I et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 3(6), 659–675 (2011).
  CASGoogle Scholar
• 7 Palarasah Y, Nielsen C, Sprogøe U et al. Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin. Exp. Immunol. 164(3), 388–395 (2011).
  Medline CASGoogle Scholar
• 8 Lee JW. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. Bioanalysis 1(8), 1461–1474 (2009). • Overall review of fit-for-purpose for biomarker assays at various stages of novel biomarker.
  CASGoogle Scholar
• 9 Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry 52(22), 3797–3806 (2013).
  Medline CASGoogle Scholar
• 10 Lin D, Alborn WE, Slebos RJC, Liebler DC. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J. Proteome Res. 12(12), 5996–6003 (2013).
  Medline CASGoogle Scholar
• 11 Kuzyk M, Parker C, Domanski D, Borchers C. Development of MRM-based assays for the absolute quantitation of plasma proteins. In: The Low Molecular Weight Proteome. Bäckvall H, Lehtiö J (Eds). Springer, New York, 53–82 (2013).
  Google Scholar
• 12 Zheng J, Mehl J, Zhu Y, Xin B, Olah T. Application and challenges in using LC–MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. Bioanalysis 6(6), 859–879 (2014).
  CASGoogle Scholar
• 13 Jiang H, Zeng J, Titsch C et al. Fully validated LC–MS/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum. Anal. Chem. 85(20), 9859–9867 (2013).
  Medline CASGoogle Scholar
• 14 Jiang H, Xu W, Titsch CA et al. Innovative use of LC–MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development. Anal. Chem. 86(5), 2673–2680 (2014).
  Medline CASGoogle Scholar
• 15 Liu G, Ji QC, Dodge R et al. Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: practical considerations in assay development and validation. J. Chromatogr. A 1284(0), 155–162 (2013).
  Medline CASGoogle Scholar
• 16 Xu K, Liu L, Maia M et al. A multiplexed hybrid LC–MS/MS pharmacokinetic assay to measure two co-administered monoclonal antibodies in a clinical study. Bioanalysis 6(13), 1781–1794 (2014).
  CASGoogle Scholar
• 17 Zhang Q, Spellman DS, Song Y et al. Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies. Anal. Chem. 86(17), 8776–8784 (2014).
  Medline CASGoogle Scholar
• 18 Yuan L, Mai A, Aubry A-F, Arnold ME, Ji QC. Feasibility assessment of a novel selective peptide derivatization strategy for sensitivity enhancement for the liquid chromatography/tandem mass spectrometry bioanalysis of protein therapeutics in serum. Rapid Commun. Mass Spectrom. 28(7), 705–712 (2014).
  Medline CASGoogle Scholar
• 19 Law WS, Genin J-C, Miess C et al. Use of generic LC–MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis 6(23), 3225–3235 (2014).
  CASGoogle Scholar
• 20 Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Meth. 9(6), 555–566 (2012).
  Medline CASGoogle Scholar
• 21 Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Meth. 10(1), 28–34 (2013).
  Medline CASGoogle Scholar
• 22 Li W, Cohen LH. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal. Chem. 75(21), 5854–5859 (2003).
  Medline CASGoogle Scholar
• 23 Neubert H, Muirhead D, Kabir M, Grace C, Cleton A, Arends R. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human β-nerve growth factor. Anal. Chem. 85(3), 1719–1726 (2013).
  Medline CASGoogle Scholar
• 24 Palandra J, Finelli A, Zhu M, Masferrer J, Neubert H. Highly specific and sensitive measurements of human and monkey interleukin 21 using sequential protein and tryptic peptide immunoaffinity LC–MS/MS. Anal. Chem. 85(11), 5522–5529 (2013).
  Medline CASGoogle Scholar
• 25 Torsetnes SB, Løvbak SG, Claus C et al. Immunocapture and LC–MS/MS for selective quantification and differentiation of the isozymes of the biomarker neuron-specific enolase in serum. J. Chromatogr. B 929(0), 125–132 (2013).
  Medline CASGoogle Scholar
• 26 Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin. Chem. 59(6), 982–990 (2013).
  Medline CASGoogle Scholar
• 27 Li H, Ortiz R, Tran L et al. General LC–MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267–1273 (2012).
  Medline CASGoogle Scholar
• 28 Li H, Ortiz R, Tran LB et al. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC–MS/MS method in rat plasma following cassette-dosing. AAPS J. 15(2), 337–346 (2013).
  Medline CASGoogle Scholar
• 29 Knutsson M, Schmidt R, Timmerman P. LC–MS/MS of large molecules in a regulated bioanalytical environment – which acceptance criteria to apply? Bioanalysis 5(18), 2211–2214 (2013).
  CASGoogle Scholar
• 30 Dufield D, Neubert H, Garofolo F et al. 2014 white paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input). Bioanalysis 6(23), 3237–3249 (2014).
  CASGoogle Scholar
• 31 Jenkins R, Duggan J, Aubry A-F et al. Recommendations for validation of LC–MS/MS bioanalytical methods for protein biotherapeutics. AAPS J. 17(1), 1–16 (2015). •• Recommendations for validation of LC–MS/MS bioanalytical methods.
  Medline CASGoogle Scholar
• 32 Gong C, Zeng J, Akinsanya B et al. Development and validation of an LC–MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. Bioanalysis 6(18), 2371–2383 (2014).
  CASGoogle Scholar
• 33 Dawes ML, Gu H, Wang J et al. Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 934, 1–7 (2013).
  Medline CASGoogle Scholar
• 34 US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for industry, bioanalytical method validation, Rockville, MD, USA (2001). www.fda.gov/downloads/Drugs/…/Guidances/ucm070107.pdf.
  Google Scholar
• 35 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. London, UK (2011). EMEA/CHMP/EWP/192217/2009. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
  Google Scholar
• 36 MacCross Lab Software: Skyline. https://brendanxuw1.gs.washington.edu/labkey/project/home/software/Skyline.
  Google Scholar
• 37 BLAST Assembled Genomes. http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome.
  Google Scholar